

SWISS HELVETIA FUND, INC.
Form N-Q
November 22, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number: 811-05128

THE SWISS HELVETIA FUND, INC.

(Exact name of registrant as specified in charter)

1270 Avenue of the Americas, Suite 400

New York, New York 10020

(Address of principle executive offices)

Alexandre de Takacsy

Hottinger et Cie

3 Place des Bergues

C.P. 395

CH-1201 Geneva

Switzerland

(Name and address of agent for service)

Registrant's telephone number, including area code: 1-888-SWISS-00

Date of fiscal year end: December 31

Date of reporting period: September 30, 2011

Item 1. Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited)

September 30, 2011

| No. of Shares | Security | Fair Value | Percent of Net Assets |
|----------------------------------|--|---------------|-----------------------------|
| Common Stocks 82.57% | | | |
| Banks 5.85% | | | |
| 240,000 | Credit Suisse Group <i>Registered Shares</i> A global diversified financial service company with significant activity in private banking, investment banking, asset management and insurance service. (Cost \$11,971,809) | \$ 6,341,517 | 1.69% |
| 1,345,000 | UBS AG^{1,2} <i>Registered Shares</i> A global diversified financial service company with significant activity in private banking, investment banking, and asset management. (Cost \$18,480,419) | 15,607,509 | 4.16% |
| | | 21,949,026 | 5.85% |
| Biotechnology 2.37% | | | |
| 48,650 | Actelion, Ltd. <i>Registered Shares</i> Biotechnology company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. (Cost \$2,494,563) | 1,622,917 | 0.43% |
| 352,155 | Addex Pharmaceuticals, Ltd.^{2,3} <i>Registered Shares</i> Bio-pharmaceutical company that discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent. (Cost \$17,167,028) | 2,911,686 | 0.78% |
| | | | Percent |
| No. of | | Fair | of Net |
| Shares | Security | Value | Assets |
| Biotechnology (continued) | | | |
| 3,829,299 | Biotie Therapies Oyj^{2,4} <i>Bearer Shares</i> Develops drugs that treat dependence disorders, inflammatory diseases, and thrombosis. (Cost \$2,118,548) | \$ 2,091,081 | 0.56% |
| 3,029 | NovImmune SA^{2,4} <i>Common Shares</i> Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. (Cost \$1,551,109) | 2,260,995 | 0.60% |
| | | 8,886,679 | 2.37% |
| Chemicals 3.18% | | | |
| 1,500 | Givaudan SA <i>Registered Shares</i> | 1,174,172 | 0.31% |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Manufactures and markets fragrances and flavors from natural and synthetic ingredients.
(Cost \$1,324,258)

| | | | |
|---------------|--|------------|-------|
| 41,000 | Syngenta AG¹ | | |
| | <i>Registered Shares</i> | 10,765,716 | 2.87% |
| | Produces herbicides, insecticides and fungicides, and seeds for field crops, vegetables, and flowers. (Cost \$13,122,961) | | |
| | | <hr/> | <hr/> |
| | | 11,939,888 | 3.18% |

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (continued)

September 30, 2011

| No. of | | Fair | Percent |
|--|---|--------------|---------|
| Shares | Security | Value | of Net |
| | | | Assets |
| Common Stocks (continued) | | | |
| Construction & Materials 1.06% | | | |
| 2,235 | Belimo Holding AG <i>Registered Shares</i> World market leader in damper and volume control actuators for ventilation and air-conditioning equipment. (Cost \$2,668,019) | \$ 3,986,238 | 1.06% |
| | | 3,986,238 | 1.06% |
| Financial Services 2.96% | | | |
| 14,700 | Allreal Holding AG <i>Registered Shares</i> Develops and manages real estate. Operates as a general contractor offering planning, architect, and construction management services. (Cost \$2,094,153) | 2,272,245 | 0.61% |
| 150,442 | Swiss Re AG¹ <i>Non-voting equity securities</i> Offers reinsurance, insurance and insurance-linked financial market products. (Cost \$7,742,543) | 7,042,600 | 1.88% |
| 42,974 | Swissquote Group Holding SA <i>Registered Shares</i> Operates an online trading system which offers customer real-time securities quotes on the Swiss Stock Exchange. (Cost \$2,368,690) | 1,771,855 | 0.47% |
| | | 11,086,700 | 2.96% |
| | | | Percent |
| No. of | | Fair | of Net |
| Shares | Security | Value | Assets |
| Food & Beverages 22.45% | | | |
| 135 | Lindt & Sprungli AG <i>Registered Shares</i> Major manufacturer of premium Swiss chocolates. (Cost \$471,625) | \$ 4,685,539 | 1.25% |
| 1,442,300 | Nestle SA¹ <i>Registered Shares</i> Largest food and beverage processing company in the world. (Cost \$38,125,322) | 79,554,365 | 21.20% |
| | | 84,239,904 | 22.45% |
| Industrial Goods & Services 9.25% | | | |
| 905,000 | ABB, Ltd.¹ | 15,712,705 | 4.19% |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

Registered Shares

The holding company for ABB Group, which is one of the largest electrical engineering firms in the world.
(Cost \$21,646,736)

14,730

Burckhardt Compression Holding AG

Bearer Shares

Produces compressors for oil refining, the chemical and petrochemical industries, industrial gases, and gas transport and storage.
(Cost \$3,721,138)

2,928,810

0.78%

6,440

Inficon Holding AG

Registered Shares

Manufactures and markets vacuum instruments used to monitor and control production processes. Manufactures on-site chemical detection and monitoring systems.
(Cost \$581,616)

943,702

0.25%

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (continued)

September 30, 2011

| No. of Shares | Security | Fair Value | Percent of Net Assets |
|--|---|---------------|-----------------------------|
| Common Stocks (continued) | | | |
| Industrial Goods & Services (continued) | | | |
| 8,100 | Kaba Holding AG, Series B Registered Shares Provides mechanical and electronic security systems. Offers individually tailored Total Access Control including high-security locking devices for heavy safes, modular access and time management applications, as well as no-contact identification technology. (Cost \$3,048,081) | \$ 2,764,505 | 0.74% |
| 54,744 | Kuehne + Nagel International AG Registered Shares Transports freight worldwide. (Cost \$4,438,559) | 6,195,842 | 1.65% |
| 2,400 | SGS SA <i>Registered Shares</i> Provides industrial inspection, analysis, testing, and verification services worldwide. (Cost \$3,903,307) | 3,672,795 | 0.98% |
| 44,544 | Zehnder Group AG <i>Bearer Shares</i> Manufactures a variety of radiators. Produces bathroom radiators, electric and aluminum radiators, as well as steel radiators. (Cost \$3,355,515) | 2,493,738 | 0.66% |
| | | 34,712,097 | 9.25% |
| | | | Percent |
| No. of Shares | Security | Fair Value | Percent of Net Assets |
| Insurance 2.82% | | | |
| 12,600 | Swiss Life Holding AG <i>Registered Shares</i> Financial services company provides life and property insurance, institutional investment management, and private banking services. (Cost \$2,159,923) | \$ 1,399,692 | 0.37% |
| 43,740 | Zurich Financial Services AG¹ Registered Shares Offers property, accident, health, automobile, liability, financial risk and life insurance and retirement products. (Cost \$10,452,957) | 9,197,776 | 2.45% |
| | | 10,597,468 | 2.82% |
| Medical Technology 1.53% | | | |
| 168,000 | Kuros Biosurgery AG^{2,4} | 2,996,367 | 0.80% |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

| | | |
|---|---|-----------------|
| <i>Common Shares</i> | | |
| Develops biomaterials and bioactive biomaterial combination products for trauma, wound and spine indications. (Cost \$2,516,639) | | |
| 3,731 | Spineart SA^{2,4} | |
| | <i>Common Shares</i> | 2,752,141 0.73% |
| | Designs and markets an innovative full range of spine products, including fusion and motion preservation devices, focusing on easy to implant high-end products to simplify the surgical act. (Cost \$2,623,329) | |
| | | _____ |
| | | 5,748,508 1.53% |

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (continued)

September 30, 2011

| No. of Shares | Security | Fair Value | Percent of Net Assets |
|---|---|----------------|-----------------------------|
| Common Stocks (continued) | | | |
| Personal & Household Goods 3.95% | | | |
| 207,700 | Compagnie Financiere Richemont SA, Series A¹ <i>Bearer Shares</i> Manufactures and retails luxury goods. Produces jewelry, watches, leather goods, writing instruments, and men's and women's wear. (Cost \$8,830,356) | \$ 9,363,993 | 2.50% |
| 16,400 | Swatch Group AG <i>Bearer Shares</i> Manufactures finished watches, movements and components. Produces components necessary to its eighteen watch brand companies. Also operates retail boutiques. (Cost \$5,005,290) | 5,458,241 | 1.45% |
| | | 14,822,234 | 3.95% |
| Pharmaceuticals 25.93% | | | |
| 1,098,000 | Novartis AG¹ <i>Registered Shares</i> One of the leading manufacturers of branded and generic pharmaceutical products. Manufactures nutrition products. (Cost \$35,800,368) | 61,409,666 | 16.37% |
| 221,600 | Roche Holding AG¹ <i>Non-voting equity securities</i> Develops and manufactures pharmaceutical and diagnostic products. Produces prescription drugs in the area of cardiovascular, infectious, autoimmune and respiratory diseases, dermatology, oncology and other areas. (Cost \$20,504,703) | 35,888,319 | 9.56% |
| | | 97,297,985 | 25.93% |
| | | | Percent |
| No. of | | Fair | of Net |
| Shares | Security | Value | Assets |
| Retailers 1.22% | | | |
| 8,912 | Galenica AG <i>Registered Shares</i> Manufactures and distributes prescription and over-the-counter drugs, toiletries and hygiene products. (Cost \$5,077,326) | \$ 4,589,440 | 1.22% |
| | | 4,589,440 | 1.22% |
| | Total Common Stocks (Cost \$255,366,890) | \$ 309,856,167 | 82.57% |
| Preferred Stocks 1.97% | | | |
| Biotechnology 1.07% | | | |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

| | | | |
|--------------|--|-----------|-------|
| 6,000 | Ixodes AG, Series B⁴ <i>Preferred Shares</i> | 1,651,437 | 0.44% |
| | Restricted to the development and production of a topical product for the treatment of borreliosis-infection and the prevention of lyme-disease after a tick bite. (Cost \$1,634,699) | | |
| 3,162 | NovImmune SA, Series B⁴ <i>Preferred Shares</i> | 2,360,273 | 0.63% |
| | Discovers and develops therapeutic monoclonal antibodies (mAbs) to treat patients suffering from immune-related disorders. (Cost \$2,062,307) | | |
| | | <hr/> | <hr/> |
| | | 4,011,710 | 1.07% |

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (continued)

September 30, 2011

| No. of Shares/ Units | Security | Fair Value | Percent of Net Assets |
|--|---|----------------|-----------------------------|
| Preferred Stocks (continued) | | | |
| Medical Technology 0.90% | | | |
| 83,611 | EyeSense AG, Series C⁴ Preferred Shares A spin-out from Ciba Vision AG. Develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. (Cost \$2,390,510) | \$ 3,391,202 | 0.90% |
| | | 3,391,202 | 0.90% |
| | Total Preferred Stocks (Cost \$6,087,516) | \$ 7,402,912 | 1.97% |
| Convertible Corporate Bond 1.46% | | | |
| Industrial Goods & Services 1.46% | | | |
| 6,500,000 | Adecco Investment Bond, 6.50%, 11/26/12 (Cost \$6,387,196) | 5,478,091 | 1.46% |
| | | 5,478,091 | 1.46% |
| | Total Convertible Corporate Bond (Cost \$6,387,196) | \$ 5,478,091 | 1.46% |
| No. of | | | Percent |
| Shares/ | | Fair | of Net |
| Units | Security | Value | Assets |
| Private Equity Limited Partnerships 3.14% | | | |
| | Aravis Biotech II - Limited Partnership^{2,4} (Cost \$2,070,060) | \$ 2,128,066 | 0.57% |
| | Zurmont Madison Private Equity, Limited Partnership^{1,2,4} (Cost \$10,606,992) | 9,633,356 | 2.57% |
| | | 9,633,356 | 2.57% |
| | Total Private Equity Limited Partnerships (Cost \$12,677,052) | \$ 11,761,422 | 3.14% |
| | Total Investments* (Cost \$280,518,654) | \$ 334,498,592 | 89.14% |
| | Other Assets Less Other Liabilities, net | 40,766,410 | 10.86% |
| | | 40,766,410 | 10.86% |
| | Net Assets | \$ 375,265,002 | 100.0% |
| | | 375,265,002 | 100.0% |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

¹ One of the ten largest portfolio holdings.

² Non-income producing security.

³ *Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company's outstanding voting securities. Transactions during the year with companies which were affiliates are as follows:*

| Name of Issuer | Shares | | Gross | | | Shares | |
|-----------------------------|--------------------------|---------------------------|-----------|------------|--------|-------------------------|--------------------------|
| | Held as of 12/31/2010 | Value as of 12/31/2010 | Additions | Reductions | Income | Held as of 9/30/2011 | Value as of 9/30/2011 |
| Addex Pharmaceuticals, Ltd. | 352,155 | \$ 3,706,298 | \$ | \$ | \$ | 352,155 | \$ 2,911,686 |

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Schedule of Investments (Unaudited) (concluded)

September 30, 2011

⁴ Illiquid. There is no public market for these securities. Securities priced at Fair Value as determined by the Board's Pricing Committee. Restricted Securities are not registered under the Securities Act of 1933, as amended, other than Rule 144A securities. At the end of the period, the aggregate value of these securities amounted to \$29,264,918 or 7.80% of the Fund's net assets. Additional information on these securities is as follows:

| Security | Acquisition Date | Acquisition Cost |
|------------------------------------|------------------------------------|------------------|
| Aravis Biotech II, LP | July 31, 2007 June 3, 2011 | \$ 2,070,060 |
| Biotie Therapies OYJ | October 17, 2008 December 13, 2010 | 2,118,548 |
| EyeSense AG Preferred Shares C | July 22, 2010 | 2,390,510 |
| Ixodes AG, Preferred Shares B | April 7, 2011 | 1,634,699 |
| Kuros Biosurgery AG | August 10, 2009 August 28, 2009 | 2,516,639 |
| NovImmune SA Common Shares | October 7, 2009 December 11, 2009 | 1,551,109 |
| NovImmune SA Preferred Shares B | October 7, 2009 December 11, 2009 | 2,062,307 |
| Spineart SA | December 22, 2010 | 2,623,329 |
| Zurmont Madison Private Equity, LP | September 13, 2007 June 14, 2011 | 10,606,992 |
| | | \$ 27,574,193 |

Effective February 2, 2011, the Fund acquired shares of Biotie Therapies OYJ in exchange for shares of Synosia Therapeutics Holding AG which were acquired during the period noted.

⁵ The Fund has a fundamental investment policy that prohibits it from investing 25% or more of its total assets in a particular industry. As of September 30, 2011, the Fund had more than 25% of its total assets invested in the pharmaceutical sector as a result of the appreciation of the value of its existing investments against the value of its overall portfolio. The Fund will not invest in any additional companies in this sector until such time as the percentage of the Fund's total assets invested in this sector is below 25%.

* Cost for Federal income tax purposes is \$283,887,738 and net unrealized appreciation (depreciation) consists of:

| | |
|--|---------------|
| Gross Unrealized Appreciation | \$ 93,929,967 |
| Gross Unrealized Depreciation | (43,319,113) |
| Net Unrealized Appreciation (Depreciation) | \$ 50,610,854 |

PORTFOLIO HOLDINGS

% of Net Assets

| | |
|-------------------------------------|--------|
| Common Stocks | |
| Pharmaceuticals | 25.93% |
| Food & Beverages | 22.45% |
| Industrial Goods & Services | 9.25% |
| Banks | 5.85% |
| Personal & Household Goods | 3.95% |
| Chemicals | 3.18% |
| Financial Services | 2.96% |
| Insurance | 2.82% |
| Biotechnology | 2.37% |
| Medical Technology | 1.53% |
| Retailers | 1.22% |
| Construction & Materials | 1.06% |
| Private Equity Limited Partnerships | 3.14% |
| Convertible Corporate Bond | 1.46% |
| Preferred Stocks | 1.97% |

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

| | |
|------------------------------|-------------------|
| Other Assets and Liabilities | 10.86% |
| | <u> </u> |
| | 100.00% |
| | <u> </u> |

See Notes to Schedule of Investments.

THE SWISS HELVETIA FUND, INC.

Notes to Schedule of Investments (Unaudited)

Note 1 Organization and Significant Accounting Policies

A. Organization

The Swiss Helvetia Fund, Inc. (the Fund) is registered under the Investment Company Act of 1940, as amended (the Act), as a non-diversified, closed-end management investment company. The Fund is organized as a corporation under the laws of the State of Delaware.

The investment objective of the Fund is to seek long-term growth of capital through investment in equity and equity-linked securities of Swiss companies. The Fund may also acquire and hold equity and equity-linked securities of non-Swiss companies in limited instances.

B. Securities Valuation

The Fund values its investments at fair value in accordance with accounting principles generally accepted in the United States (GAAP).

When valuing listed equity securities, the Fund uses the last sale price prior to the calculation of the Fund's net asset value (NAV). When valuing equity securities that are not listed or that are listed but have not traded, the Fund uses the mean between the bid and asked prices for that day.

When valuing fixed-income securities, the Fund uses the last bid price prior to the calculation of the Fund's NAV. If a current bid price is not available, the Fund uses the mean between the last quoted bid and asked prices. When valuing fixed-income securities that mature within sixty days, the Fund uses amortized cost, which approximates fair value.

It is the responsibility of the Fund's Board of Directors (the Board) to establish fair valuation procedures. When valuing securities for which market quotations are not readily available, or for which the market quotations that are available are considered unreliable, the Fund determines a fair value in good faith in accordance with these procedures (a Fair Value). The Fund may use these procedures to establish the Fair Value of securities when, for example, a significant event occurs between the time the market closes and the time the Fund values its investments. After consideration of various factors, the Fund may value the securities at their last reported price or at some other value. Additional consideration is given to securities that have experienced a decrease in the volume or level of activity or to circumstances that indicate that a transaction is not orderly.

Swiss exchange-listed options or options that are not listed at the request of a counterparty are valued using implied volatilities as input into widely accepted models (e.g., Black-Scholes). Eurex-listed options are valued at their most recent sale price (latest bid for long options and the latest ask for short options), or if there are no such sales, at the average of the most recent bid and asked quotations, or if such quotations are not available, at the last bid quotation in the case of purchased options or the last asked quotation in the case of written options; however, if there are no such quotations, such contracts will be valued using the implied volatilities observed for similar options as an input to a model. Options traded in the over-the-counter market are valued at the price communicated by the counterparty to the option, which typically is the price at

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

which the counterparty would close out the transaction.

The Fund is permitted to invest in alternative investments which do not have readily available market quotations. For such investments, the Act requires the Board to determine their Fair Value. The Fund's investments of this type have been Fair Valued at \$29,264,918, or 7.80% of the Fund's net assets at September 30, 2011, and are listed in Note 4 to the Schedule of Investments. These investments also are considered Level 3 investments under GAAP as described below.

THE SWISS HELVETIA FUND, INC.

Notes to Schedule of Investments (Unaudited) (continued)

Various inputs are used to determine the value of the Fund's investments. These inputs are summarized in the three broad levels listed below:

Level 1 quoted prices in active markets for identical assets and liabilities

Level 2 other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)

Level 3 significant unobservable inputs (including the Fund's own assumptions in determining the Fair Value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund's net assets as of September 30, 2011:

| | Level 1 Quoted Prices | Level 2 Other Significant Observable Inputs | Level 3 Significant Unobservable Inputs | Total |
|--|--------------------------|---|---|-----------------------|
| Investments in Securities | | | | |
| Common Stock* | \$ 299,755,582 | \$ | \$ 10,100,584 | \$ 309,856,167 |
| Preferred Stock | | | 7,402,912 | 7,402,912 |
| Convertible Corporate Bond | | 5,478,091 | | 5,478,091 |
| Private Equity Limited Partnerships | | | 11,761,422 | 11,761,422 |
| Total Investments in Securities | \$ 299,755,582 | \$ 5,478,091 | \$ 29,264,918 | \$ 334,498,592 |

* Please see the Schedule of Investments for Industry classifications.

The inputs and valuation techniques used to value Level 2 securities, which consist of an exchange-listed corporate convertible bond, are based on a pricing service model, which may include consideration of dealer quotes, trade execution data, conversion prices compared to the current market quotation of the underlying stock and, when available, the last sale price on the exchange on which it trades.

Level 3 securities consist of the Fund's investments in privately-held companies and the Fund's investments in limited partnerships (private equity partnerships) that invest in privately-held companies, which are listed in Note 4 to the Schedule of Investments.

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer;

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

and the issuer's prospects, including any recent or potential management or capital structure changes.

The Fund values its Level 3 investments in private equity partnerships in accordance with Accounting Standards Codification 820-10-35, *Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)* (ASC 820-10-35). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund's measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnerships and their portfolio holdings provided by the partnerships' general partners or managers, other available information about the partnerships' portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnerships' general partners or managers and/or other limited partners and comparisons of previously-obtained estimates against the partnerships' audited financial statements. In using the NAV as a practical expedient,

 THE SWISS HELVETIA FUND, INC.

Notes to Schedule of Investments (Unaudited) (continued)

dent, certain attributes of the investment that may impact the fair value of the investment are not considered in measuring fair value. Attributes of those investments include the investment strategies of the privately held companies and may also include, but are not limited to, restrictions on the investor's ability to redeem its investments at the measurement date and any unfunded commitments.

When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately-held company or private equity partnership. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis.

The Fund has adopted a policy of recognizing significant transfers between all Levels based on their market prices at the reporting period end. For the nine-month period ended September 30, 2011, there were no significant transfers between Level 1, Level 2, and Level 3.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

| | Common Stock | Preferred Stock | Private Equity Limited Partnerships | Total |
|--|---------------|-----------------|---|---------------|
| Balance as of December 31, 2011 | \$ 7,804,991 | \$ 5,650,685 | \$ 8,845,515 | \$ 22,301,191 |
| Change in Unrealized Appreciation/Depreciation | 177,045 | 382,892 | 12,084 | 572,021 |
| Net Realized Gain (Loss) | | | | |
| Gross Purchases | 2,118,548 | 3,487,883 | 2,903,823 | 8,510,254 |
| Gross Sales | | (2,118,548) | | (2,118,548) |
| Balance as of September 30, 2011 | \$ 10,100,584 | \$ 7,402,912 | \$ 11,761,422 | \$ 29,264,918 |

C. New Accounting Pronouncement

In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2011-04 Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS (ASU 2011-04), which includes common requirements for measurement of and disclosure about fair value between U.S. GAAP and IFRS. ASU 2011-04 will require reporting entities to disclose quantitative information about the unobservable inputs used in the fair value measurements categorized within Level 3 of the fair value hierarchy. In addition, ASU 2011-04 will require reporting entities to make disclosures about amounts and reasons for all transfers in and out of Levels 1 and 2 of the fair value hierarchy. The new and revised disclosures are effective for interim and annual reporting periods beginning after December 15, 2011. Management is currently evaluating the implications of ASU 2011-04 and its impact on the financial statements and related disclosures has not yet been determined.

D. When-Issued and Delayed-Delivery Transactions

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

The Fund may purchase or sell securities on a when-issued or delayed-delivery basis. The Fund records when-issued or delayed-delivery securities as of trade date and maintains security positions such that sufficient liquid assets will be available to make payment for the securities purchased. Securities purchased on a when-issued or delayed-delivery basis are marked-to-market daily and, in the case of fixed-income securities, begin earning interest on the settlement date. The Fund may dispose of or renegotiate a delayed-delivery transaction after it is entered into, which may result in a capital gain or loss. Losses may occur on these transactions due to changes in market conditions or the failure of counterparties to perform under the contract.

E. Options

The Fund may buy call options and put options, and may sell (write) covered call options. Options may be entered into on securities in which the Fund may invest and on Swiss stock indices. Option contracts are utilized to manage the Fund's exposure to changing security prices and to generate income. Purchasing call options tends to increase the Fund's exposure to the underlying instrument.

THE SWISS HELVETIA FUND, INC.

Notes to Schedule of Investments (Unaudited) (continued)

Purchasing put options tends to decrease the Fund's exposure to the underlying instrument. The Fund pays a premium as an investment that is subsequently marked-to-market to reflect the current value of the option purchased. Premiums paid for purchasing options which expire are treated as realized losses. The risk associated with purchasing put and call options is limited to the premium paid and the exposure to the risk that the counterparty would be unable to meet the terms of the contract. Premiums paid for purchasing options which are exercised or closed are added to the amounts paid or offset against the proceeds on the underlying instrument to determine the realized gain or loss.

Writing call options tends to decrease the Fund's exposure to the underlying instrument. When the Fund writes a call option, such option is covered, meaning that the Fund holds the underlying instrument subject to being called by the option counterparty. When the Fund writes a call option, an amount equal to the premium received is recorded as a liability and subsequently marked-to-market to reflect the current value of the option written. Premiums received from writing options which expire are treated as realized gains. Premiums received from writing options which are exercised or closed are added to the proceeds or offset against amounts paid on the underlying instrument to determine the realized gain or loss. The Fund as a writer of an option has no control over whether the option will be exercised and, as a result, bears the market risk of an unfavorable change in the price of the instrument underlying the written option. There is the risk the Fund may not be able to enter into a closing transaction because of an illiquid market.

The Fund did not have any written call option transactions during the nine-month period ended September 30, 2011, and the Fund held no contracts at September 30, 2011.

F. Foreign Currency Translation

The Fund maintains its accounting records in U.S. dollars. The Fund's assets are invested primarily in Swiss equities and equity-linked securities. In addition, the Fund makes its temporary investments in Swiss franc-denominated bank deposits, short-term debt securities and money market instruments. Substantially all income received by the Fund is in Swiss francs. The Fund's NAV, however, is reported, and distributions from the Fund are made, in U.S. dollars resulting in gain or loss from currency conversions in the ordinary course of business. Historically, the Fund has not entered into transactions designed to reduce currency risk and does not intend to do so in the future. The cost basis of foreign denominated assets and liabilities is determined on the date that they are first recorded within the Fund and translated to U.S. dollars. These assets and liabilities are subsequently valued each day at prevailing exchange rates. The difference between the original cost and current value denominated in U.S. dollars is recorded as unrealized foreign currency gain/loss. In valuing securities transactions, the receipt of income and the payment of expenses, the Fund uses the prevailing exchange rate on the transaction date.

G. Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Schedule of Investments. Actual results could differ from those estimates.

H. Concentration of Market Risk

Edgar Filing: SWISS HELVETIA FUND, INC. - Form N-Q

The Fund primarily invests in securities of Swiss issuers. Such investments may carry certain risks not ordinarily associated with investments in securities of U.S. issuers. These risks include future political and economic developments, unfavorable movements in the U.S. dollar relative to the Swiss franc, and the possible imposition of exchange controls and changes in governmental law and restrictions. In addition, concentrations of investments in securities of issuers located in a specific region exposes the Fund to the economic and government policies of that region and may increase risk compared to a fund whose investments are more diversified.

THE SWISS HELVETIA FUND, INC.

Notes to Schedule of Investments (Unaudited) (concluded)

Note 2 Capital Commitments

As of September 30, 2011, the Fund invested in private equity partnerships and preferred stock. The Fund's investments are summarized in the Schedule of Investments. The Fund's capital commitments and the amounts disbursed to the private equity partnerships and the issuer of preferred stock are shown in the table below:

| <u>Investments</u> | Original Capital Commitment* | Unfunded Commitments | Fair Value as of September 30, 2011 |
|--|---------------------------------|-------------------------|--|
| Private Equity Limited Partnerships International (a) | | | |
| Aravis Biotech II LP | \$ 3,578,113 | \$ 1,164,318 | \$ 2,128,066 |
| Zurmont Madison Private Equity LP | 15,413,410 | 3,117,569 | 9,633,356 |
| Preferred Stock International | | | |
| EyeSense AG, Series C (b) | 3,082,689 | 616,537 | 3,391,202 |

* The original capital commitment represents 3,250,000, 14,000,000 and 2,800,006 Swiss francs for Aravis Biotech II LP, Zurmont Madison Private Equity LP and EyeSense AG, respectively. The exchange rate as of September 30, 2011 was used for conversion and equals 0.9083.

(a) This category includes two private equity limited partnerships that invest primarily in ventures, biotechnology and in management buyout of industrial and consumer goods companies. There is no redemption right for the interests in these two funds. Instead, the nature of the investments in this category is that distributions are received through the realization of the underlying assets of a fund. If these investments were held, it is estimated that the underlying assets of each fund would be realized over 4 to 6 years.

(b) The unfunded commitment for this security represents future payments contingent upon contractual milestones achieved by EyeSense.

THE SCHEDULE OF INVESTMENTS SHOULD BE READ IN CONJUNCTION WITH THE FINANCIAL STATEMENTS AND NOTES TO FINANCIAL STATEMENTS WHICH ARE INCLUDED IN THE FUND'S SEMI-ANNUAL REPORT OR AUDITED ANNUAL REPORT. THESE REPORTS INCLUDE ADDITIONAL INFORMATION ABOUT CERTAIN SECURITY TYPES INVESTED IN BY THE FUND.

Item 2. Controls and Procedures.

- (a) The registrant's principal executive officer and principal financial officer have concluded, based on their evaluation of the registrant's disclosure controls and procedures as conducted within 90 days of the filing date of this report, that these disclosure controls and procedures are adequately designed and are operating effectively to ensure that information required to be disclosed by the registrant on Form N-Q is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

- (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d))) that occurred during the registrant's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3. Exhibits.

Certifications pursuant to Rule 30a-2(a) are attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant): The Swiss Helvetia Fund, Inc.

By (Signature and Title)*: /s/ RUDOLF MILLISITS
Rudolf Millisits,

Chief Executive Officer

Date: November 22, 2011

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)*: /s/ RUDOLF MILLISITS
Rudolf Millisits,

Chief Executive Officer

Date: November 22, 2011

By (Signature and Title)*: /s/ RUDOLF MILLISITS
Rudolf Millisits,

Chief Financial Officer

Date: November 22, 2011